DNTH
Dianthus Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$108.10
+0.23%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$1.02
- Revenue estimate
- $400.8K
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$0.90
- EPS estimate
- -$0.85
- Revenue actual
- $761.0K
- Revenue estimate
- $297.2K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -8.5%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $140
- PT range
- $122 – $158
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026